Found: 3
Select item for more details and to access through your institution.
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
- Published in:
- QJM: An International Journal of Medicine, 2011, v. 104, n. 11, p. 957
- By:
- Publication type:
- Article
PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 235, doi. 10.1002/hon.47_2630
- By:
- Publication type:
- Article
PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 235, doi. 10.1002/hon.47_2630
- By:
- Publication type:
- Article